Cargando…
Efficacy of Implantable Cardioverter-defibrillators for Secondary Prevention of Sudden Cardiac Death in Patients with End-stage Renal Disease
End-stage renal disease (ESRD) constitutes a major burden on the health-care system in the United States, with more than 300,000 patients nationwide being treated with renal replacement therapy. Very few studies to date have evaluated the benefit of implantable cardioverter-defibrillator (ICD) impla...
Autores principales: | Payne, Taylor, Waller, Jennifer, Kheda, Mufaddal, Nahman, N. Stanley, Maalouf, Joyce, Gopal, Aaron, Hreibe, Haitham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MediaSphere Medical
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452739/ https://www.ncbi.nlm.nih.gov/pubmed/32874746 http://dx.doi.org/10.19102/icrm.2020.110803 |
Ejemplares similares
-
Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016) -
Implantable Cardioverter‐Defibrillators for Secondary Prevention of Sudden Cardiac Death: A Review
por: Borne, Ryan T., et al.
Publicado: (2017) -
Incidence, risk factors and distribution of syphilis in the end-stage renal disease population in the USA
por: Weathers, Erena N, et al.
Publicado: (2019) -
Use of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in Asia
por: Ueda, Nobuhiko, et al.
Publicado: (2023) -
Mortality risk after herpes zoster infection in end-stage renal disease patients
por: Ahn, John H, et al.
Publicado: (2018)